Selected MAS Publications

An international consensus survey of diagnostic criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis. Davì S, Consolaro A, Guseinova D, Pistorio A, Ruperto N, Martini A, Cron RQ, Ravelli A; MAS Study Group. J Rheumatol. 2011 Apr;38(4):764-8. PMID:  21285158.

Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment. Ravelli A, Grom AA, Behrens EM, Cron RQ. Genes Immun. 2012 Jun;13(4):289-98. PMID:  22418018.

Intensive care requirement, rather than degree of serum ferritin elevation, predicts mortality in macrophage activation syndrome. Mannion ML, Cron RQ. Pediatr Crit Care Med. 2012 Sep;13(5):616; author reply 616-7. PMID:  22955471.

Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients. Miettunen PM, Narendran A, Jayanthan A, Behrens EM, Cron RQ. Rheumatology (Oxford). 2010 Aug 7. [Epub ahead of print] PMID: 20693540.  .pdf

Evaluation of the presentation of systemic onset juvenile rheumatoid arthritis: data from the Pennsylvania Systemic Onset Juvenile Arthritis Registry (PASOJAR). Behrens EM, Beukelman T, Gallo L, Spangler J, Rosenkranz M, Arkachaisri T, Ayala R, Groh B, Finkel TH, Cron RQ. J Rheumatol. 2008 Feb;35(2):343-8. Epub 2007 Dec 15.PMID: 18085728.  .pdf

Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. Behrens EM, Beukelman T, Paessler M, Cron RQ. J Rheumatol. 2007 May;34(5):1133-8. Epub 2007 Mar 1.PMID: 17343315.  .pdf

Interleukin 1 receptor antagonist to treat cytophagic histiocytic panniculitis with secondary hemophagocytic lymphohistiocytosis. Behrens EM, Kreiger PA, Cherian S, Cron RQ. J Rheumatol. 2006 Oct;33(10):2081-4.PMID: 17014024.  .pdf